MCL1 and neoplasm: While we acknowledge proteomic analysis of these patient samples could be skewed by components of the tumor immune microenvironment, BRAFi resistance may at least in part be attributed to a Mcl-1 regulated minority MOMP-like phenotype (Fig. 7), paralleling our observations of MDA-T32.